Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States

Jia, X., Zhao, Y., Carrico, J., Brodtkorb, T-H., Mendelsohn, A., Lowry, S., Feldman, S., Wu, JJ., & Armstrong, A. (2018). Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States. Journal of managed care & specialty pharmacy, 24(10-a Suppl), S79. https://doi.org/10.18553/jmcp.2018.24.10-a.s1

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Long-term effects of a diet supplement containing Cannabis sativa oil and Boswellia serrata in dogs with osteoarthritis following physiotherapy treatments
Article

The influence of mediators on the relationship between antenatal opioid agonist exposure and the severity of neonatal opioid withdrawal syndrome
Article

A scoping review of empirical research on prescription drug promotion